i
Coronavirus disease 2019 (COVID-19) : commercial laboratory seroprevalence survey data
-
July 21, 2020
[PDF-212.42 KB]
Details:
-
Corporate Authors:
-
Description:Updated July 21, 2020
CDC is partnering with commercial laboratories to conduct and publish results from a large-scale geographic seroprevalence survey that has tested de-identified clinical blood specimens from Connecticut, Louisiana, Minnesota, Missouri, New York City, Philadelphia, San Francisco, South Florida, Utah and Western Washington State for SARS-CoV-2 antibodies.
The survey includes people who had blood specimens tested for reasons unrelated to COVID-19, such as for a routine or sick visit during which blood was collected and tested by commercial laboratories in participating areas from each of the 10 sites. CDC aims to test about 1,800 samples collected from each of these 10 areas, approximately every 3–4 weeks. The results of these subsequent analyses are available on our interactive website and will be updated as samples continue to be analyzed. Researchers are looking to see what percentage of people tested already have antibodies against SARS-CoV-2, and how that percentage changes over time in each area.
-
Subjects:
-
Document Type:
-
Place as Subject:
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
